文献速递湿疹皮炎与荨麻疹

中重度特应性皮炎的真实世界临床、心理社会与经济负担:多国研究

Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-09-25

MEASURE-AD 是一项在 28 个国家开展的横断面研究,纳入 1591 例医生确诊的中重度特应性皮炎(AD)患者(其中 1558 例符合全部入组标准并纳入分析),评估其临床、心理社会与经济负担。结果显示,98.4% 的患者使用 AD 药物,56% 接受系统治疗,最常用系统治疗为度普利尤单抗(56.3%)、系统糖皮质激素(18.1%)和甲氨蝶呤(16.2%)。总体人群平均最严重瘙痒数字评分(WP-NRS)为 5.3,平均皮肤病生活质量指数(DLQI)为 10.8,平均儿童 DLQI(CDLQI)为 9.6;接受系统治疗的患者疾病负担低于未接受系统治疗者。

要点

  • 98.4% 的患者使用 AD 药物,56% 接受系统治疗,其中 15% 为系统单药治疗。
  • 最常用系统治疗为度普利尤单抗(56.3%)、系统糖皮质激素(18.1%)和甲氨蝶呤(16.2%)。
  • 总体人群平均 WP-NRS 为 5.3,≥55% 的患者报告中度至重度瘙痒(WP-NRS ≥4)。

核心结论

  • 尽管系统治疗可降低总体疾病负担,中重度 AD 患者仍存在显著的多维度疾病负担和疾病控制不佳。

研究设计与样本

  • MEASURE-AD 为横断面、28 国研究,纳入医生确诊的中重度 AD 且正在接受或符合系统治疗条件的患者(≥12 岁),2019 年 12 月至 2020 年 12 月于常规门诊就诊时入组;共入组 1591 例,其中 1558 例(1434 例成人、124 例青少年)符合全部患者选择标准并纳入分析。

主要发现

  • 总体人群中 98.4% 使用 AD 药物,56% 接受系统药物治疗(15% 为系统单药治疗)。
  • 最常用系统治疗为度普利尤单抗(56.3%)、系统糖皮质激素(18.1%)和甲氨蝶呤(16.2%)。
  • 总体人群平均 WP-NRS 为 5.3,≥55% 的患者报告中度至重度瘙痒(WP-NRS ≥4)。
  • 总体人群平均 DLQI 为 10.8,平均 CDLQI 为 9.6。
  • 亚组分析显示,接受系统治疗的患者疾病负担低于未接受系统药物治疗者。

临床怎么用

  • 本研究描述的真实世界治疗模式和疾病负担可用于了解中重度 AD 患者的临床、心理社会及经济负担。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis (AD), a relapsing, inflammatory skin disease, is associated with pruritus that can negatively affect patients' quality of life. Understanding the burden of AD is critical for informing and tailoring treatment and disease management to improve patient outcomes. This study characterized global treatment patterns and the clinical, psychosocial and economic burden of moderate-to-severe AD. METHODS: MEASURE-AD was a cross-sectional 28-country study in patients with physician-confirmed moderate-to-severe AD who were either receiving or eligible for systemic therapy for AD. Patients ≥12 years were enrolled between December 2019 and December 2020 while attending routine office or clinic visit. Primary outcomes included Worst Pruritus Numeric Rating Scale (WP-NRS; range: 0-10) and Dermatology Life Quality Index (DLQI; range: 0-30) and Children's DLQI (CDLQI; range: 0-30). Secondary outcomes included physician- and patient-reported clinical, psychosocial and economic burden. RESULTS: Of the 1591 patients enrolled, 1558 (1434 adults and 124 adolescents) fulfilled all patient selection criteria and were included in this analysis. Almost all patients (98.4%) in the total population were using AD medications and more than half (56%) were receiving systemic medication (15% systemic monotherapy). The most used systemic therapies were dupilumab (56.3%), systemic glucocorticoids (18.1%) and methotrexate (16.2%). Mean WP-NRS was 5.3 in the total population, and most patients (≥55%) reported moderate-to-severe pruritus (WP-NRS ≥4). Mean DLQI was 10.8 and mean CDLQI was 9.6. Secondary endpoints demonstrated substantial clinical, psychosocial, and economic burden of disease. Subgroup analysis demonstrated that patients receiving systemic therapy had lower disease burden than those not taking systemic medications. CONCLUSIONS: While systemic therapy lowers overall disease burden, patients with moderate-to-severe AD continue to have substantial multidimensional disease burden and uncontrolled disease. Overall, there is a need for effective disease management, including effective treatments that improve patients' psychosocial outcomes and reduce the economic burden of AD.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Eyerich K, Gooderham MJ, Silvestre JF, et al. Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study. J Eur Acad Dermatol Venereol. 2023. PMID: 37669868. doi:10.1111/jdv.19500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。